Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GD versus IE as second-line chemotherapy for advanced soft tissue sarcoma
ChiCTR1800016587Phase 2Not yet recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Jul 2018
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial in soft tissue sarcoma (STS) comparing Gemcitabine with Docetaxel Group with Ifosfamide with Etoposide Group (2 arms). Primary endpoint: Progression-free survival. Planned start Jul 2018; status: not yet recruiting.
02
Drugs
gemcitabinedocetaxelifosfamideetoposide
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on ChiCTR1800016587.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800016587.